Global Pipeline Review and Analysis of Hematological Malignancies

The markets segments for therapeutics for hematological malignancies are numerous and complicated. The historical general conception that relatively low prevalence diseases, has been insufficient in size to allow companies to quickly regain their investment is clearly out of date. In this perspective enhanced development is expected. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule apoptotic inducers and kinase inhibitors are as well in the forefront.

About this report

In this unique report, Global Pipeline Review & Analysis of Hematological Malignancies, BioSeeker reports on the hematological cancer pipeline by:

Investigator - Includes 212 investigators and partners

Drug - Includes 237 "active" drugs

Sub-indication - Includes 11 sub-indications

Developmental stage - Includes 8 developmental stages

Compound type - Includes 21 different compounds types

Targeted therapy strategy - Includes 5 different targeted therapy strategies

Target - Includes 97 different protein targets

Signaling pathway - Includes 18 different signaling pathways

All of above "factors" are cross referenced against each other, generating highly valuable insights in 40 figures and 53 tables. Read more below about each "factor" included in this cutting edge analysis.

Investigator

This report includes 212 investigators and partners from all over the world.

Drug

There are today more than 237 therapeutics for the treatment of hematological cancers, from early preclinical to marketed drugs. Each drug is annotated with a brief drug description.

Sub-indication

The hematological cancer drug pipeline is broken down into 11 sub-indications:

Cancer, leukemia, acute lymphocytic

Cancer, leukemia, acute myelogenous

Cancer, leukemia, chronic lymphocytic

Cancer, leukemia, chronic myelogenous

Cancer, leukemia, general

Cancer, leukemia, hairy cell

Cancer, lymphoma, B-cell

Cancer, lymphoma, general

Cancer, lymphoma, Hodgkin`s

Cancer, lymphoma, non-Hodgkin`s

Cancer, lymphoma, T-cell

Only the highest developmental stage per drug and indication is accounted for.

Developmental Stage

Each sub-indication of a drug is described with its developmental stage:

Preclinical

Clinical Trial

Phase I Clinical Trial

Phase II Clinical Trial

Phase III Clinical Trial

Pre-registration

Registered

Marketed

Compound Type

BioSeeker has described all 237 drugs in the hematological malignancies pipeline with its corresponding compound type:

Biological

Biological, bacterial cells

Biological, cellular, autologous

Biological, cellular, heterologous

Biological, nucleic acid

Biological, nucleic acid, non-viral vector

Biological, nucleic acid, viral vector

Biological, peptide

Biological, peptide, recombinant

Biological, protein

Biological, protein, antibody

Biological, protein, recombinant

Chemical, semisynthetic

Chemical, synthetic

Chemical, synthetic, isomeric

Chemical, synthetic, nucleic acid

Chemical, synthetic, peptide

Natural product

Natural product, animal

Natural product, bacterial

Natural product, plant

When available, drug compounds are further described with chemical name, CAS number, chemical formula and molecular weight.

Targeted Therapy Strategy

This report categorizes available drugs into 5 major targeted therapy strategies:

1.Angiogenesis

2. Antibody

3. Apoptosis

4. Protein Kinase Inhibitors

5. Vaccines

Target

This analysis includes 97 protein targets, linked to 165 drugs for the treatment of hematological cancers. All protein targets are described by its primary localization, molecular class, molecular function, and biological process:

Primary Localization of Target:

Cell surface

Centrosome

Cytoplasm

Cytosol

Endoplasmic reticulum

Extracellular

Integral to membrane

Lysosome

Mitochondrial membrane

Mitochondrion

Nucleus

Plasma membrane

Secretory granule

Molecular Class of Target:

Adapter molecule

Adhesion molecule

Cell cycle control protein

Cell surface receptor

Chaperone

Cysteine protease

Cytokine

Cytokine receptor

Cytoskeletal protein

DNA methyltransferase

DNA polymerase

DNA repair protein

Enzyme: Deaminase

Enzyme: Decarboxylase

Enzyme: Hydrolase

Enzyme: Ligase

Enzyme: Oxidoreductase

Enzyme: Phosphorylase

Enzyme: Topoisomerase

Enzyme: Transferase

G protein coupled receptor

Growth factor

Integral membrane protein

Ligand

Lipid phosphatase

Membrane bound ligand

MHC complex protein

Nuclear receptor

Receptor tyrosine kinase

Serine protease

Serine/threonine kinase

T cell antigen receptor

Transcription factor

Transcription regulatory protein

Translation regulatory protein

Transport/cargo protein

Tyrosine kinase

Unclassified

Molecular Function of Target:

Carboxy-lyase activity

Cell adhesion molecule activity

Chaperone activity

Cysteine-type peptidase activity

Cytokine activity

Deaminase activity

DNA repair protein

DNA topoisomerase activity

DNA-directed DNA polymerase activity

DNA-methyltransferase activity

G-protein coupled receptor activity

Growth factor activity

Hydrolase activity

Kinase activity

Ligand-dependent nuclear receptor activity

Ligase activity

Lipid phosphatase activity

MHC class I receptor activity

Molecular function unknown

Oxidoreductase activity

Phosphorylase activity

Protein binding

Protein serine/threonine kinase activity

Protein-tyrosine kinase activity

Receptor activity

Receptor binding

Receptor signaling complex scaffold activity

Serine-type peptidase activity

Structural constituent of cytoskeleton

T cell receptor activity

Transcription factor activity

Transcription regulator activity

Transferase activity

Translation regulator activity

Transmembrane receptor activity

Transmembrane receptor protein tyrosine kinase activity

Transporter activity

Unclassified

Biological Process of Target:

Anti-apoptosis

Apoptosis

Cell communication

Cell communication ; Cell surface receptor linked signal transduction

Cell communication ; Signal transduction

Cell communication ; Signal transduction ; Transport

Cell growth and/or maintenance

Enzyme linked receptor protein signaling pathway ; Cellular morphogenesis during differentiation

Immune response

Metabolism

Metabolism ; Energy pathways

Protein metabolism

Protein modification

Regulation of cell cycle

Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism

Signal transduction

Transport

Signaling Pathway

The 97 available protein targets have been compared with molecular entities in known signaling pathways. This analysis showed the involvement of hematological drugs in at least 18 different signaling pathways:

Alpha6 Beta4 Integrin Signaling Pathway

Androgen Receptor Signaling Pathway

B Cell Receptor Signaling Pathway

EGFR1 Signaling Pathway

ID Signaling Pathway

IL-1 Singaling Pathway

IL-2 Signaling Pathway

IL-3 Signaling Pathway

IL-4 Signaling Pathway

IL-5 Signaling Pathway

IL-6 Signaling Pathway

IL-7 Signaling Pathway

Kit Receptor Signaling Pathway

Notch Signaling Pathway

T Cell Receptor Signaling Pathway

TGF-beta Receptor Signaling Pathway

TNF-alpha Signaling Pathway

Wnt Signaling Pathway

March 2007 195 Pages
Table of Contents
Price: $3,795.00 / GBP1,897.50